NEC (n=7) | No NEC (n=48) | P value | |
Gestational age (weeks) | 33.2 (31.4–36.4) | 35.0 (28.3–38.5) | 0.72 |
Sex (female) | 3 (43%) | 18 (38%) | 0.5 |
Birth weight (g) | 1390 (920–2380) | 1800 (950–2875) | 0.73 |
SGA | 3 (43%) | 17 (35%) | 0.7 |
Apgar score<7 at 5 min of life | 1 (14.3%) | 8 (16.7%) | 0.73 |
Haemodynamically significant patent ductus arteriosus | 0 | 5 (10.4%) | – |
Respiratory support when diazoxide was commenced | |||
None or low flow | 6 (86%) | 35 (73%) | 0.66 |
Non-invasive ventilation | 1 (14%) | 11 (23%) | 1.0 |
Invasive ventilation | 0 | 2 (4%) | 1.0 |
Sepsis | 2 (28.6%) | 7 (14.6%) | 0.61 |
Transfusion | 1 (14.3%) | 11 (22.9%) | 1.0 |
Congenital anomalies | 2 (28.6%) | 10 (20.8%) | 0.64 |
Human milk | 3 (43%) | 28 (58%) | 0.45 |
Human milk fortification | 3 (42.9%) | 32 (66.7%) | 0.21 |
Carbohydrate energy supplement† | 6 (85.7%) | 34 (70.8%) | 0.13 |
GIR at diazoxide start of treatment (mg/kg/min) | 13 (12–14) | 13.95 (12.45–16.75) | 0.36 |
Age at diazoxide treatment (days) | 9 (7–19) | 18 (11–35) | 0.13 |
Postmenstrual age at diazoxide treatment (weeks) | 36 (32.4–37.6) | 37.6 (33.5–41.1) | 0.36 |
Diazoxide initial dose (mg/kg/day) | 9 (5–10)‡ | 10 (2.5–12.5)‡ | 0.95 |
Diazoxide maximum dose (mg/kg/day) | 10 (7–10)‡ | 10 (5–17.5)‡ | 0.94 |
Octreotide | 1 (14%) | 3 (6%) | 0.43 |
Data are median (IQR) or percentage.
*Includes non-invasive positive pressure ventilation, continuous possitive airway pressure(CPAP) and high flow nasal cannula.
†Maltodextrin (Polycal, Nutricia).
‡Mean (range).
§
GIR, glucose infusion rate; NEC, necrotising enterocolitis; SGA, small for gestational age.